New weight loss drug reduces AHI in certain patients
By HME News Staff
Updated 11:53 AM CDT, Wed April 17, 2024
INDIANAPOLIS – Eli Lilly and Company’s tirzepatide injection diabetes and weight loss drug may help reduce AHI in patients with sleep apnea, according to the results of the company’s phase 3 clinical trials. The Surmount-OSA Study 1 evaluated tirzepatide in adults with moderate-to-severe OSA and obesity who were not on PAP therapy for 52 weeks. Tirzepatide led to a mean AHI reduction from baseline of 27.4 events per hour compared to a mean AHI reduction from baseline of 4.8 events per hour for placebo. In key secondary outcomes, tirzepatide led to a mean AHI reduction from baseline of 55.0% compared to 5.0% from baseline for placebo; tirzepatide also led to a mean body weight reduction of 18.1% from baseline, compared to 1.3% from baseline for placebo. "OSA impacts 80 million adults in the U.S., with more than 20 million living with moderate-to-severe OSA. However, 85% of OSA cases go undiagnosed and therefore untreated," said Jeff Emmick, MD, Ph.D., senior vice president, product development, Lilly. "Addressing this unmet need head-on is critical, and while there are pharmaceutical treatments for the excessive sleepiness associated with OSA, tirzepatide has the potential to be the first pharmaceutical treatment for the underlying disease."
Comments